Astrazeneca plc’s buyout of Amplimmune Inc. for $225 million up front could put the pipeline-strapped pharma giant high on the short list of leaders in combination immunotherapy, if the latter’s early stage candidates pan out, and the deal carries another $275 million in potential milestone payments.